Get in Touch
ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.
Reliable Network Performance in Schizophrenia Trials
An interventional Phase 2 study evaluating the therapeutic efficacy, safety profile, and tolerability of two predefined once-daily oral doses of M4- selective IP versus placebo in individuals with schizophrenia undergoing acute psychotic exacerbation.
- ERG was top enroller
- ERG sites averaged 3.2 subjects per month
- 33% Screen Fail Rate
6 Weeks
In Patient Treatment
28 Days
Follow-up
15 Days
Screening
Top-Enrolling Site
Woodland International Research Group was the top-enrolling site in this Phase 2 schizophrenia study. The team leveraged well established referral relationships and dedicated outreach team to deliver superior results.
Sustained Recruitment Across ERG Network
During the active recruitment period, ERG inpatient sites sustained an average identification rate of approximately 3.2 eligible subjects per month. This consistent performance supports aggressive but achievable enrollment projections for future schizophrenia programs.
Efficient Screening in Schizophrenia Population
On average, the ERG network achieved a 33% screen failure rate in this schizophrenia study, reflecting rigorous operational processes and deep diagnostic expertise. This efficiency reduces timeline risk and optimizes sponsors resources.
